Profile of anterior gradient 3 (AGR3) mRNA expression and serum levels in benign and malignant breast tumors

Issue title: Second International Conference on Women and Societal Perspective on Quality of Life (WOSQUAL-2020)

Guest editors: Andi Nilawati Usman

Article type: Research Article

Authors: Prihantono, Prihantono^a; | Rahardjo, Warsinggih^a | Syamsu, Salman Ardi^a | Smaradhania, Nilam^a

Affiliations: [a] Department of Surgery, Hasanuddin University, Makassar, Indonesia

Correspondence: [*] Corresponding author: Prihantono Prihantono, Department of Surgery, Hasanuddin University, Makassar, Indonesia. E-mail: [email protected]

Abstract: BACKGROUND:Benign and malignant breast tumors are the most commonly diagnosed tumor in females. Early and accurate diagnosis of malignancy is essential for effective breast cancer treatment. Human anterior gradient 3 (AGR3) has been suggested as a potential biomarker for the early detection and prognostic determination of breast cancer. OBJECTIVE:This study profiles AGR3 mRNA expression and serum protein levels in patients with benign and malignant breast tumors. METHODS:A case-control study was conducted on 40 benign and 40 malignant breast tumor patients in Makassar, Indonesia. AGR3 mRNA and protein were detected using qRT-PCR and ELISA, respectively. RESULTS:This study found significantly higher AGR3 mRNA expression in benign than malignant breast tumors using qRT-PCR (p < 0.001). In contrast, ELISA revealed no significant difference between AGR3 serum protein levels in benign and malignant breast tumors (p = 0.507). CONCLUSIONS:AGR3 is associated with non-aggressive tumors and could be used as a marker for less aggressive breast tumors.

Keywords: Anterior gradient 3 (AGR3), breast tumors, biomarker, mRNA expression, serum levels

DOI: 10.3233/BD-219006

Journal: Breast Disease, vol. 40, no. s1, pp. S39-S43, 2021